Acute Ischemic Stroke Drugs Market to Reach $17.62 Billion by 2029 at 5.8% CAGR

 With a focus on usability, this report equips professionals with the latest industry insights to stay ahead in the competitive acute ischemic stroke drugs market.



What Is The Projected Market Size & Growth Rate Of The Acute Ischemic Stroke Drugs Market?
The acute ischemic stroke drugs market size has grown steadily in recent years. It will grow from $13.5 billion in 2024 to $14.07 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to increasing incidence of stroke, government initiatives and healthcare policies, increased awareness and education, strategic collaborations and partnerships, aging population

The acute ischemic stroke drugs market size is expected to see strong growth in the next few years. It will grow to $17.62 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to emerging therapies and drug pipeline, precision medicine and personalized therapies, global healthcare infrastructure development, increasing healthcare expenditure, telemedicine and remote patient monitoring. Major trends in the forecast period include advancements in thrombolytic therapies, neuroprotective agents development, personalized medicine and biomarker research, telemedicine and remote monitoring, collaborations and strategic partnerships.

Get your free sample today:
Acute Ischemic Stroke Drugs Market Report 2025, Overview By 2034 Sample

What Is The Crucial Factor Driving The Global Acute Ischemic Stroke Drugs Market?
The rise in the prevalence of chronic diseases is anticipated to propel the growth of the acute ischemic stroke drug market in the coming years. Chronic diseases, also known as non-communicable diseases, refer to conditions that endure for a year or longer and necessitate continuing medical care, restrict everyday activities, or both. The primary causes of death and disability are chronic illnesses such as heart disease, cancer, and diabetes. Acute ischemic stroke drugs are primarily used in chronic diseases to reduce the chances of clot formation and strokes and restore blood flow to the brain. For instance, in September 2022, according to the reports shared by the World Health Organization (WHO), a Switzerland-based health agency, due to chronic diseases, it is estimated 41 million people die each year, which is equivalent to 74% of all deaths globally, and 17 million individuals die before the age of 70 from chronic diseases. By 2025, an estimated 164 million Americans, or nearly 49% of the population, would be living with chronic illnesses. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the acute ischemic stroke drug market.

Segment Covered In The Acute Ischemic Stroke Drugs Market Report
The acute ischemic stroke drugs market covered in this report is segmented –

1) By Type: Tablet, Capsule, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Hospitals, Diagnostic Centers, Other Applications

Subsegments:
1) By Tablet: Immediate Release Tablets, Extended Release Tablets, Orally Disintegrating Tablets
2) By Capsule: Hard Shell Capsules, Soft Gelatin Capsules, Extended Release Capsules
3) By Other Types: Injectable Solutions, Intravenous (IV) Preparations, Inhalation Formulations

Emerging Trends And Strategic Opportunities In The Acute Ischemic Stroke Drugs Market
Major companies operating in the acute ischemic stroke drug market are developing innovative formulations, such as sublingual formulations of edaravone and dexborneol for acute ischemic stroke. A sublingual formulation of edaravone and dexborneol is a medication designed to be placed under the tongue for rapid absorption into the bloodstream, combining the antioxidant and anti-inflammatory effects of both compounds to enhance treatment efficacy. For instance, in October 2024, Simcere Pharmaceutical, a China-based pharmaceutical company, granted breakthrough therapy designation to Sanbexin, a sublingual formulation of edaravone and dexborneol, for treating acute ischemic stroke (AIS). This designation was based on promising results from the TASTE-SL phase 3 clinical trial (NCT04950920), where 64.4% of patients treated with Sanbexin achieved a modified Rankin Scale (mRS) score of =1 at 90 days, compared to 54.7% in the placebo group. The treatment, which can be administered outside of hospital settings, aims to reduce disability and improve outcomes in AIS patients.

Key Player In The Acute Ischemic Stroke Drugs Market
Major companies operating in the acute ischemic stroke drugs market include F. Hoffmann-La Roche AG, C.H. Boehringer Sohn AG & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, AstraZeneca plc, ZZ Biotech LLC, NoNO Inc., Biogen Inc., Athersys Inc., Bayer AG, Sanofi S.A., Pfizer Inc., DiaMedica Therapeutics, Lumosa Therapeutics Co. Ltd., Johnson & Johnson, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals LLC, Nanjing Yoko Biomedical Co. Ltd., TrueBinding Inc., GNT Pharma Co. Ltd., aptaTargets SL, NuvOX Pharma, Simcere Pharmaceutical Co. Ltd., Genentech Inc., Pharming Technologies B.V., SanBio BV, Revalesio Corporation, Stemedica Cell Technologies Inc., CorInnova Incorporated, Phagenesis

View the full acute ischemic stroke drugs market report here:
Acute Ischemic Stroke Drugs Market Report 2025, Overview By 2034

Global Acute Ischemic Stroke Drugs Market - Regional Insights:
North America was the largest region in the acute ischemic stroke drugs market in http://2024.Asia-Pacific is expected to be the fastest-growing region in the global acute ischemic stroke drugs market report during the forecast period. The regions covered in the acute ischemic stroke drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: The Business Research Company | LinkedIn

Comments

Post a Comment

Popular posts from this blog

Future of the Antifungals Market: Insights, Developments, and Strategic Overview

Image
 Ideal for market intelligence professionals and business strategists, this research uncovers where growth is headed in the antifungals industry. Antifungals Market Valuation Forecast: What Will The Market Be Worth By 2025? The antifungals market size has grown strongly in recent years. It will grow from $27.16 billion in 2024 to $29.6 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to fungal disease prevalence, aging population, healthcare infrastructure, awareness and education. The antifungals market size is expected to see strong growth in the next few years. It will grow to $41.2 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to emerging fungal strains, regulatory approvals, global health concerns, increased healthcare spending, patient education and awareness. Major trends in the forecast period include research and development, ...
Read more

Polybutylene Terephthalate (PBT) Market Analysis 2025 – Supporting High-Stakes Corporate Planning

Image
 This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Polybutylene Terephthalate (PBT) industry. What is the projected value of the polybutylene terephthalate (pbt) market by 2029? The polybutylene terephthalate (PBT) market size has grown strongly in recent years. It will grow from $2.5 billion in 2024 to $2.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to adoption in new industries, global economic conditions, electrical vehicle adoption, consumer goods and textile applications, advancements in material properties. The polybutylene terephthalate (PBT) market size is expected to see strong growth in the next few years. It will grow to $3.4 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to continued focus on...
Read more

Zero Trust Security Market Report 2025 – Insights for Decision Makers and Market Strategists

Image
 For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034. What is the forecasted revenue size of the zero trust security industry by 2029? The zero trust security market size has grown rapidly in recent years. It will grow from $38.45 billion in 2024 to $45.05 billion in 2025 at a compound annual growth rate (CAGR) of 17.2%. The growth in the historic period can be attributed to cyber threat landscape, legacy security challenges, digital transformation, remote workforce trend, data privacy concerns. The zero trust security market size is expected to see exponential growth in the next few years. It will grow to $99.24 billion in 2029 at a compound annual growth rate (CAGR) of 21.8%. The growth in the forecast period can be attributed to threat intelligence integration, user-centric security approach, data volume growth, business co...
Read more